SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.06+0.3%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (8422)1/22/1999 2:32:00 PM
From: Bluegreen  Read Replies (1) of 17367
 
Cacaito, this is the way I understand it and I may be totally wrong. First, when Xoma was setting up the trial with the FDA it was centered around time and total death because of money concerns by Xoma and small sample concerns by FDA. It appears the total death requirement has not changed although the enrollment numbers are far more than imagined by anyone. No matter what an interim analysis shows on efficacy, if total death was not reached then no early halt due to overwhelming efficacy. We were led to believe by Xoma that all the interim analysis had to show was overwhelming efficacy, not overwhelming efficacy AND total death number requirement. It is an outrage that total death number was not changed according to surprise increase in patient enrollment. This is where the FDA pound of flesh thinking comes into play. Only my opinions and thoughts, I could once again be totally wrong so call Ellen for yourself.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News